Navidea Biopharmaceuticals Announces 2015 Annual Meeting Results
July 16 2015 - 5:16PM
Business Wire
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) today
announced the results of voting at its 2015 Annual Meeting of
Stockholders (the Annual Meeting) held July 16, 2015. Approximately
80 percent of outstanding shares were represented at the
meeting.
At the Annual Meeting, Navidea’s stockholders:
- Elected Gordon A. Troup to the Navidea
Board of Directors to serve for a term of three years; and
- Ratified the appointment of BDO USA,
LLP to act as the Company’s independent registered public
accounting firm for 2015.
The final results are subject to verification by the independent
election inspectors and will be reported in a Form 8-K to be filed
by Navidea with the Securities and Exchange Commission in the next
few days.
Following the formal business portion of the Annual Meeting,
Rick Gonzalez, Navidea President and CEO, made a brief presentation
to stockholders in attendance at the Annual Meeting, including
overviews on the following:
- Lymphoseek® (technetium Tc-99m
tilmanocept) injection U.S. commercialization and life cycle
management activities; and
- Manocept™ CD206 targeting platform
update, including a discussion of Macrophage Therapeutics
development activities.
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a
biopharmaceutical company focused on the development and
commercialization of precision diagnostics, therapeutics and
radiopharmaceutical agents. Navidea is developing multiple
precision-targeted products and platforms including Manocept™ and
NAV4694 to help identify the sites and pathways of undetected
disease and enable better diagnostic accuracy, clinical
decision-making, targeted treatment and, ultimately, patient care.
Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s
first commercial product from the Manocept platform, was approved
by the FDA in March 2013 and in Europe in November 2014. Navidea’s
strategy is to deliver superior growth and shareholder return by
bringing to market novel radiopharmaceutical agents and
therapeutics, and advancing the Company’s pipeline through global
partnering and commercialization efforts. For more information,
please visit www.navidea.com.
The Private Securities Litigation Reform Act of 1995 (the Act)
provides a safe harbor for forward-looking statements made by or on
behalf of the Company. Statements in this news release, which
relate to other than strictly historical facts, such as statements
about the Company’s plans and strategies, expectations for future
financial performance, new and existing products and technologies,
anticipated clinical and regulatory pathways, and markets for the
Company’s products are forward-looking statements within the
meaning of the Act. The words “believe,” “expect,” “anticipate,”
“estimate,” “project,” and similar expressions identify
forward-looking statements that speak only as of the date hereof.
Investors are cautioned that such statements involve risks and
uncertainties that could cause actual results to differ materially
from historical or anticipated results due to many factors
including, but not limited to, the Company’s continuing operating
losses, uncertainty of market acceptance of its products, reliance
on third party manufacturers, accumulated deficit, future capital
needs, uncertainty of capital funding, dependence on limited
product line and distribution channels, competition, limited
marketing and manufacturing experience, risks of development of new
products, regulatory risks and other risks detailed in the
Company’s most recent Annual Report on Form 10-K and other
Securities and Exchange Commission filings. The Company undertakes
no obligation to publicly update or revise any forward-looking
statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150716006586/en/
Navidea BiopharmaceuticalsTom Baker,
617-532-0624tbaker@navidea.comorSharon Correia,
978-655-2686Associate Director, Corporate Communications
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Apr 2023 to Apr 2024